Phase II Trial of Zemplar (19-Nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Paricalcitol (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 Jan 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 31 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.